{
    "clinical_study": {
        "@rank": "146419", 
        "arm_group": [
            {
                "arm_group_label": "original Clopidogrel Bisulfate (Plavix\u00ae)", 
                "arm_group_type": "Active Comparator", 
                "description": "original Clopidogrel Bisulfate (Plavix\u00ae) 600mg loading"
            }, 
            {
                "arm_group_label": "generic Clopidogrel Bisulfate (Plavitor\u00ae)", 
                "arm_group_type": "Experimental", 
                "description": "generic Clopidogrel Bisulfate (Plavitor\u00ae) 600mg loading"
            }
        ], 
        "brief_summary": {
            "textblock": "This study demonstrates the effect of generic clopidogrel bisulfate (Plavitor\u00ae) in\n      comparison with the original clopidogrel bisulfate (Plavix\u00ae) in patients with acute coronary\n      syndrome."
        }, 
        "brief_title": "Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor\u00ae) With Original Clopidogrel Bisulfate (Plavix\u00ae)", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with unstable angina or non-ST elevation myocardial infarction\n\n          2. Patients who are planned coronary angiography\n\n          3. Age >18 years, <75 years\n\n          4. Patients who agree to the study protocol\n\n        Exclusion Criteria:\n\n          1. Recent treatment with clopidogrel or pletaal or glycoprotein IIb/IIIa Rc antagonist\n\n          2. Active bleeding (peptic ulcer, trauma or intra-cranial hemorrhage)\n\n          3. Allergy to antiplatelet agent\n\n          4. Bleeding diasthesis (blood coagulation disorders, uncontrolled severe hypertension,\n             history of severe bleeding)\n\n          5. History of drug abuse or alcohol abuse\n\n          6. ST elevation myocardial infarction\n\n          7. Pregnancy\n\n          8. Low platelet count (< 100,000 /L) or abnormal results of PT or PTT\n\n          9. Liver disease ( bilirubin > 2 mg/dL, AST or ALT > 100 IU)\n\n         10. Renal failure ( Cr > 2.0 mg/dL)\n\n         11. Malignancy\n\n         12. Proton pump inhibitor, NSAIDs  statin (except atorvastatin)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060786", 
            "org_study_id": "Plavitor"
        }, 
        "intervention": [
            {
                "arm_group_label": "generic Clopidogrel Bisulfate (Plavitor\u00ae)", 
                "intervention_name": "generic clopidogrel (Plavitor\u00ae )", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "original Clopidogrel Bisulfate (Plavix\u00ae)", 
                "intervention_name": "original clopidogrel (Plavix\u00ae )", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Ticlopidine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Antiplatelet; clopidogrel; acute coronary syndrome", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Suwon", 
                    "country": "Korea, Republic of", 
                    "zip": "443-720"
                }, 
                "name": "Ajou University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor\u00ae) With Original Clopidogrel Bisulfate (Plavix\u00ae)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "PRU level at 2 hours after clopidogrel loading", 
            "safety_issue": "No", 
            "time_frame": "2 hours after clopidogrel loading"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060786"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ajou University School of Medicine", 
            "investigator_full_name": "Seung-Jea Tahk", 
            "investigator_title": "MD,PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "PRU level by VerifyNow P2Y12 at 4 -, 8- and  24 hours after clopidogrel loading", 
                "safety_issue": "No", 
                "time_frame": "4 -, 8- and  24 hours after clopidogrel loading"
            }, 
            {
                "measure": "ARU level by VerifyNow before and 2 hours after loading", 
                "safety_issue": "No", 
                "time_frame": "2 hours after loading"
            }, 
            {
                "measure": "Composite of death, myocardial infarction, target vessel revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "at 30 days"
            }, 
            {
                "measure": "Stent thrombosis by Academic Research Consortium definition", 
                "safety_issue": "Yes", 
                "time_frame": "at 30 days"
            }, 
            {
                "measure": "Incidence of TIMI major bleedings", 
                "safety_issue": "Yes", 
                "time_frame": "at 30 days"
            }
        ], 
        "source": "Ajou University School of Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "Dong-A Pharmaceutical Corporation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Ajou University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}